The scRN-Seq analysis from the HPA revealed that ORMDL2 was highly expressed in TAMs and glioma stem-like cells (GSCs), two major contributors to immune evasion and therapeutic resistance in GBM. This evidence concerns the gene ORMDL2 and glioblastoma.